FIELD: medicine, medicinal industry, pharmacy. SUBSTANCE: invention relates to a composition showing analgetic, anti-inflammatory, antipyretic and spasmolytic effect. Pharmaceutical composition comprises as active substances drotaverine hydrochloride, fenpyverinium bromide and pitophenone hydrochloride and as accessory substances potato starch, lactose, polyvinylpyrrolidone, magnesium stearate. Pharmaceutical composition is made as tablet or capsule and tablet can be covered by envelope. Invention provides wide possibilities for the use of the preparation in medicinal therapy in different fields of medicine and ensures to decrease both atropine and papaverine adverse effects. Preparation shows strong spasmolytic and analgetic properties being without narcotic effect, its use does not cause drug addiction effect and its toxicity is minimal. Time of effect onset of preparation is decreased vastly and therefore does not result to adverse effects on blood picture (granulocytopenia). EFFECT: valuable medicinal properties of composition, decreased toxicity, enhanced efficiency. 6 cl
Title | Year | Author | Number |
---|---|---|---|
SPASMOLYTIC TABLETS BRALANGIN | 2001 |
|
RU2203041C1 |
SPASMOLYTIC COMPOSITION, METHOD TO OBTAIN SPASMOLYTIC COMPOSITION | 1997 |
|
RU2182016C2 |
PHARMACEUTICAL COMPOSITION SHOWING SPASMOLYTIC ACTIVITY, METHOD OF ITS PREPARING | 2001 |
|
RU2183119C1 |
COMBINED ANALGESIC AND ANTI-SPASMODIC DRUG | 2012 |
|
RU2500399C2 |
SPASMOLYTIC MEDICINAL AGENT | 2002 |
|
RU2232018C2 |
PREPARATION ELICITING ANALGETIC, ANTRIPYRETIC AND SPASMOLYTIC EFFECT | 2003 |
|
RU2235544C1 |
NEW THERAPEUTIC COMPOSITION FOR TREATING PAIN SYNDROME ACCOMPANYING SMOOTH MUSCLE SPASM | 2012 |
|
RU2497505C1 |
METHOD FOR OBTAINING SPASMOLYTIC MEDICINAL PREPARATION | 2003 |
|
RU2252024C2 |
DOSAGE FORM FOR RELEASING DROTAVERINE IN ORAL CAVITY | 2019 |
|
RU2729659C1 |
ANTI-ARRHYTHMIC, ANTI-ANGINAL PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2212236C1 |
Authors
Dates
2002-06-10—Published
2001-07-10—Filed